SCHEMBL7072948

SCHEMBL7072948

C=CCOc1ccc2c(=O)c(C)c(-c3ccccc3)oc2c1C(=O)C=Cc1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KRAS P01116 3/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
KMT2A Q03164 1/20 0.42
PLIN1 O60240 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
PLIN5 Q00G26 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ABHD5 Q8WTS1 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
ALDH1A1 P00352 1/20 0.40
ABCB1 P08183 2/20 0.40
TNFRSF1A P19438 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072240 0.91 ALOX5 (0.50) KRASLMNAMAPTPDE4APDE4B
SCHEMBL7070595 0.90 MAOB (0.40) LMNAMAPTPDE4AGAARAB9A
SCHEMBL7070128 0.90 KRAS (0.42) KRASLMNAMAPTPDE4APDE4B
SCHEMBL7192689 0.88 KRAS (0.42) KRASLMNAMAPTPDE4APDE4B
SCHEMBL7070733 0.88 NQO1 (0.45) LMNAMAPTKMT2APLIN1GAA
SCHEMBL7068041 0.81 ALDH1A1 (0.44) LMNAMAPTPDE4AKMT2AGAA
SCHEMBL7073297 0.81 MAOB (0.43) LMNAMAPTPDE4AKMT2AGAA
SCHEMBL7069986 0.79 ABCB1 (0.46) LMNAMAPTKMT2AABCB1ALOX5
SCHEMBL7072943 0.79 ALDH1A1 (0.41) LMNAMAPTGAAHTTRAB9A
SCHEMBL7073634 0.78 NQO1 (0.45) LMNAMAPTPLIN1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6620842-B2 Chalcones INDENA SPA (IT) 2003-09-16 US claimed
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP claimed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US claimed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP claimed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO claimed
US-6620842-B2 Chalcones INDENA SPA (IT) 2003-09-16 US disclosed
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP disclosed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US disclosed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth HDGF, MKI67, HPD KRAS 1768/4885LMNA 4635/4885MAPT 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.